|
Getting your Trinity Audio player ready...
|
Below are grounded historical cases where important work was blocked, delayed, or nearly lost because the grant-and-institutional system rewarded consensus, credentials, fashionable topics, or short-term plausibility over real scientific value. The counterfactual “AIIM would help” is not certain history; it is a plausible mechanism analysis based on AIIM’s stated model: funding scientists by published output, measurable contribution, public evidence, and impact, without requiring a degree, grant-writing success, or committee approval. Science DAO describes AI Internet-Meritocracy as funding by “AI-assessed contributions and measurable research impact,” and says users need “neither a science degree, nor grant writing” if they have published research or software.
1. Katalin Karikó and mRNA therapeutics: grants rejected for decades
Discovery: Modified mRNA technology, later foundational for COVID-19 mRNA vaccines.
Failure mode: A high-value research direction looked too risky, unfashionable, and technically impractical to conventional funders.
Karikó’s case is one of the clearest modern examples. A 2023 review in Biomedicines says Karikó and Weissman’s 2005 modified-mRNA discovery was delayed in adoption partly because of “lack of funding for mRNA research,” perceived risk, and scientific skepticism. A National Bureau of Economic Research chapter on risky research reports that Karikó “repeatedly failed to get funding,” quoting her description that grant applications came back “no, no, no,” and even speculates that earlier support might have accelerated mRNA vaccine readiness before later outbreaks. Times Higher Education also reports that Karikó was demoted at Penn in 1995 because her work was viewed as unproductive by institutional standards.
Why this matters: mRNA vaccines became one of the central biomedical technologies of the COVID-19 era. The grant system did not merely miss a minor idea; it underweighted a platform technology.
How AIIM could have helped:
AIIM would not need to predict “COVID-19 vaccines” decades in advance. It could have funded Karikó because she had a persistent public research trail around a bottleneck technology: therapeutic mRNA. Instead of asking, “Will a grant panel believe this proposal now?”, AIIM could ask:
Is this researcher producing technically coherent work with high dependency potential for future medicine?
That is exactly where continuous, contribution-based funding is stronger than one-off grant panels. Karikó’s work would likely have accumulated score through papers, citations, later dependencies, and expert/public signals — even while committees remained skeptical.
2. Stanley Prusiner and prions: “heresy” before the Nobel Prize
Discovery: Prions — infectious proteinaceous agents — eventually awarded the 1997 Nobel Prize in Physiology or Medicine.
Failure mode: A radical hypothesis violated the dominant theoretical model of infectious disease.
The American Association of Immunologists notes that Prusiner’s tenure was at stake and that the Howard Hughes Medical Institute had informed him his funding would not be renewed; publication of his 1982 Science article helped salvage his ability to continue. A 2024 interview in Journal of Biological Chemistry says Prusiner’s ideas were rejected by HHMI and by many virologists, neurologists, and medical scientists. The Royal Society summarizes the eventual outcome: Prusiner was awarded a Nobel Prize for discovering prions.
Why this matters: Prion biology changed neuroscience, infectious-disease theory, and understanding of diseases such as Creutzfeldt-Jakob disease and bovine spongiform encephalopathy.
How AIIM could have helped:
A grant panel can punish “impossible-sounding” mechanisms. AIIM could instead track whether a claim is generating reproducible evidence, new methods, citations, and downstream research. Even if the initial theory looked strange, a contribution-based system could keep small but real funding flowing while evidence accumulated.
This is especially important for discoveries that are anti-paradigmatic: they are not merely “new facts,” but attacks on the field’s assumptions. Those are exactly the cases where peer committees are structurally fragile. ⚗️
3. Jeffrey Hall and circadian rhythms: Nobel-level work, later funding exhaustion
Discovery: Molecular mechanisms of circadian rhythm; 2017 Nobel Prize in Physiology or Medicine with Michael Rosbash and Michael Young.
Failure mode: Long-term basic science became hard to sustain when funding culture shifted toward administrative pressure, fashion, and institutional politics.
Quartz reported that Jeffrey Hall said he left science because he ran out of money and was fed up with academia. The Independent likewise reported that Hall said he left science due to lack of funding and “institutional corruption.” The Nobel Prize press release confirms that Hall, Rosbash, and Young received the 2017 Nobel for discoveries of molecular mechanisms controlling circadian rhythm.
Why this matters: Circadian biology is now central to sleep research, metabolism, neuroscience, pharmacology, and public health.
How AIIM could have helped:
Hall’s case is not just “a grant was rejected before the discovery.” It shows a different failure: even a world-class basic scientist can be pushed out when funding becomes unstable or bureaucratically hostile.
AIIM could help by giving researchers an independent income stream based on their existing corpus and dependency graph. A scientist whose work becomes foundational should not have to repeatedly re-sell himself to committees every few years. Under AIIM, the funding signal would follow the scientific dependency network, not only future grant promises.
4. Barry Marshall and Robin Warren: H. pylori, ulcers, and rejected early recognition
Discovery: Helicobacter pylori as a cause of gastritis and peptic ulcer disease; Nobel Prize in 2005.
Failure mode: Medical dogma delayed acceptance of a correct causal theory.
This is not a clean “grant rejection” case, but it is a strong case of scientific gatekeeping failure closely related to grants: a radical discovery was discounted because it contradicted accepted medical doctrine. The AMA Journal of Ethics says Marshall and Warren’s claim that ulcers were caused by H. pylori was initially widely ridiculed. A historical timeline reports that in 1983 the Gastroenterological Society of Australia rejected Marshall’s abstract, ranking it in the bottom 10% of submissions, though the work later became Nobel-winning. The Nobel-related BMJ report states that the Nobel committee awarded Marshall and Warren for the 1982 discovery of H. pylori and its role in gastritis and peptic ulcer disease.
Why this matters: The discovery changed treatment from chronic acid suppression toward antibiotic eradication for many ulcers.
How AIIM could have helped:
Grant committees and conference committees often share the same cognitive failure: they ask whether the work fits current expert expectations. AIIM would be more useful if it rewarded:
- public evidence,
- independent replication,
- clinical utility,
- downstream adoption,
- and correction of wrong consensus.
In this case, once H. pylori evidence began accumulating internationally, AIIM could have routed funding and attention toward the discovery faster than status-based institutions did.
5. Hans Krebs and the citric acid cycle: journal rejection of Nobel-level biology
Discovery: The citric acid cycle, central to cellular metabolism.
Failure mode: Publication gatekeeping failed to recognize a foundational result.
This is not a grant case, but it is relevant because grant systems often depend on the same peer-review culture. Derek Lowe in Science notes that the original Krebs cycle paper was rejected by Nature, and that a later editor called it one of the journal’s biggest mistakes. ScienceAlert also lists Krebs’s citric-acid-cycle paper among rejected papers that later underpinned Nobel-winning work.
Why this matters: The citric acid cycle is one of the core mechanisms of biochemistry.
How AIIM could have helped:
AIIM could reduce dependence on a single editorial or committee bottleneck. If a manuscript is public, technically inspectable, and later becomes cited or reused, funding can flow after evidence appears. That is a major distinction:
Traditional grants must approve before work happens.
AIIM can reward after visible contribution exists.
This is closer to an automated scientific prize layer than a classical proposal contest; Science DAO explicitly frames AIIM as a practical system to automate scientific prizes and augment or replace grants.
6. Systemic evidence: top rejected grant applicants can outperform funded applicants
The problem is not only anecdotal. A meta-evaluation of grant decisions found that when researchers compared awarded applicants with rejected applicants, the most eminent rejected applicants could score better than awardees on citation impact.
Why this matters:
This suggests that grant peer review is not merely “occasionally unlucky.” It can systematically mis-rank high-impact people. That is exactly the failure AIIM is designed to attack.
How AIIM could have helped:
Instead of one binary decision — funded or rejected — AIIM would allow continuous scoring and continuous payment. A researcher rejected by a committee would not become invisible. Their work could still receive funding as its public value becomes measurable.
Pattern: what failed?
| Case | What the system undervalued | Later proof of importance | AIIM mechanism that helps |
|---|---|---|---|
| Karikó / mRNA | Risky platform technology | Nobel + COVID-19 vaccines | Continuous funding by technical contribution and dependency potential |
| Prusiner / prions | Anti-paradigm theory | Nobel + new disease model | Funding despite consensus hostility if evidence accumulates |
| Hall / circadian clocks | Long-term basic science | Nobel + broad biomedical relevance | Sustained income based on corpus and impact |
| Marshall & Warren / H. pylori | Dogma-breaking clinical causality | Nobel + changed ulcer treatment | Reward replication, utility, and downstream adoption |
| Krebs / citric acid cycle | Foundational but initially rejected theory | Nobel-level biochemistry | Post-publication reward, not single-gate approval |
| Rejected grant applicants | Mis-ranked talent | Citation-impact evidence | Continuous scoring instead of binary grant selection |
Bottom line
The grants system often fails when a discovery is:
- too early, like mRNA therapeutics;
- too heretical, like prions;
- too basic, like circadian clocks;
- too anti-dogma, like H. pylori;
- too hard to evaluate in advance, like many foundational papers.
AIIM’s strongest claim is not that AI can magically know the future. The stronger claim is narrower and more defensible:
AIIM would reduce the damage from failed grant decisions by funding visible scientific contribution continuously, transparently, and post-publication, instead of forcing all science through proposal committees.
Relevant internal links: AI Internet-Meritocracy, AIIM as an automated scientific prize, and donation page.
